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Background: The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic
oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.
Methods: oral cyclophosphamide (Endoxan®, Baxter, Italy) was administered at the dose of 50 mg daily, continuously.
Treatment-related toxicity and response to treatment were assessed by the NCI-CTC criteria, and RECIST criteria,
respectively. Progression-free (PFS), and overall survival (OS) were also assessed.
Results: 54 patients were analyzed: 20 patients (37.0%) were considered primarily platinum refractory/resistant, while 34
patients (63.0%) were defined as platinum sensitive; 79.6% of patients had received ≥2 previous lines before starting
MOC. The objective response rate (ORR) was 20.4%. Eleven patients (20.4%) experienced stable disease and 8 of them
had a response duration ≥6 months. A total of 32 patients (59.2.%) progressed during treatment. Median PFS was
4 months, and the 12-month PFS rate was 19.6%; median OS was 13 months, and the 12-month OS rate was 51.5% .
Patients responding to MOC showed a more favorable PFS (median = 17 months) compared to patients with
stabilization (median = 6 months) or progression of disease (median = 3 months) (p value = 0.0001). Median OS of
responding patients was 30 months compared to 11 months in cases achieving stabilization, or progression of disease
(median = 8 months) (p value = 0.0001). Only 1 patient experienced grade 3 anemia. Non-hematological grade 3 toxicity
was registered in 2 patients.
Conclusions: MOC could provide a valid alternative in terms of risk/benefit ratio in the palliative treatment of heavily
treated ROC patients.
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Despite the advances in surgical efforts, and the achieve-
ment of high response rates with standard platinum/pac-
litaxel front-line treatment, ovarian cancer remains the
most lethal gynaecological malignancy with a 5-year sur-
vival rate of 25-30% in advanced stage disease [1,2].
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unless otherwise stated.by the extent of residual tumor at primary surgery, and
sensitivity to platinum-based chemotherapy [3,4]. In par-
ticular, patients recurring within 6 months from initial
therapy exhibit low rates of response (4-23%) to salvage
treatment, and a median overall survival of approximately
a year [3]. In this clinical setting, special attention has to
be paid to the issue of palliation of symptoms and preser-
vation of quality of life which remain the most realistic ob-
jectives. Conversely, patients who recur >12 months after
initial therapy are defined as fully platinum sensitive, and
are usually re-challenged to platinum based combinations
[4], while patients with a platinum free interval withintral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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partially platinum sensitive, and seem to attain rates of re-
sponse to platinum re-challenge similar to those achieved
with non platinum agents [5]. Given the higher chance of
response to chemotherapy and the more favorable prog-
nosis compared to platinum refractory/resistant setting,
platinum sensitive patients often undergo several lines of
treatments with the intent to prolong survival while main-
taining an acceptable quality of life.
In this context, besides privileging less toxic drugs,
oral administration, and outpatient setting rather than
hospital-based therapies, also the frequent or even con-
tinuous administration of low dose chemotherapy (i.e.
metronomic chemotherapy) has gained much attention
in recent years; indeed, this route of drug administration
has been shown to be as active and, in some circum-
stances, even more efficacious than conventionally ad-
ministered chemotherapy, in spite of a negligible toxicity
[6-9]. Antitumor activity induced by metronomic drug
administration has been ascribed mainly to its anti-
angiogenetic effects [7-10]; however, the documentation
that metronomic chemotherapy activates antitumor im-
munity as well as tumor dormancy and senescence has
established metronomic chemotherapy as a sort of multi-
targeted treatment [11,12].
In the scenario of palliative treatments for heavily
treated, recurrent ovarian cancer (ROC) patients, much at-
tention has been focused on metronomic oral cyclophos-
phamide (MOC): in particular, very early experiences had
suggested its possible activity in advanced ovarian cancer
patients failing treatment or not amenable to surgery or
radiotherapy [13]. More recently, anedoctal cases and
small sample series have highlighted the promising rates
of response to MOC in ROC patients [14-16].
These observations prompted us to evaluate in a retro-
spective, multicenter study the efficacy as well as toxicity of
MOC in a population of very heavily treated ROC patients.
Methods
Study design
This is a multicenter, retrospective, uncontrolled study
aimed at evaluating the activity of MOC as single agent
in heavily treated ROC patients.
Written informed consent to treatment and to use of
clinical data for scientific purposes had been provided by
all patients at time of chemotherapy administration. Retro-
spective collection of clinical data from clinical charts was
approved by the Catholic University Ethic Committee and
Institutional review Board of Rome (RPN A2116).
Clinical data were collected from four Italian Institu-
tions which had employed single agent MOC in relapsed
ovarian cancer patients since April 2007 and April 2013.
Consecutive patients with histologically confirmed epi-
thelial ovarian carcinoma, previously treated with at leastone platinum/paclitaxel regimen, and with radiological
evidence of measurable recurrence/progression of dis-
ease were included in the study. Further selection cri-
teria were: age over 18 years, Eastern Cooperative
Oncology Group (ECOG) performance status ≤ 2, life
expectancy >3 months, absolute neutrophil count
(ANC) >1,500/mm3; platelets count >150,000/mm3;
bilirubin and creatinine levels less than 1.5 times the
upper limit of normal; normal cardiac function defined
as LVEF ≥ 50%. Pre-treatment evaluation included pel-
vic examination, abdomino-pelvic CT, Ca125 assay.
All patients were prescribed oral cyclophosphamide
(Endoxan®, Baxter, Italy) at the dose of 50 mg daily, con-
tinuously Treatment cycle was considered as lasting
30 days. Treatment-related toxicity was assessed accord-
ing to NCI-CTC criteria (version 2.0) [17] for patients
completing at least one cycle of therapy.
Assessment of response and clinical outcome
Response to treatment was classified according to
RECIST criteria (version 1.0) [18]. Patients with rapidly
progressive disease, early death from malignant disease
or unknown response because of insufficient or un-
known data were considered as failing to respond to
treatment (progression of disease). Response was also
evaluated according to Ca125 levels (GCIG criteria) [19].
Progression-free (PFS), and overall survival (OS) were
also assessed.
Statistical analysis
The χ2 test or Fisher’s exact test for proportion or
Mann–Whitney non parametric test were used to
analyze the distribution of categorical or continuous data
between groups.
Objective response rate (ORR) included complete and
partial response. Clinical benefit included complete, par-
tial response, and stabilization of disease. The 95% confi-
dence intervals (95% CI), have been provided. PFS was
defined as the time elapsed between start of treatment
and documentation of progressive disease or the date
last seen; OS was defined as time elapsed between start
of CTX and date of death or the date of last follow-up.
Medians and life tables were computed using the
product-limit estimate by the Kaplan and Meier method
[20] and the log-rank test was employed to assess the
statistical significance [21]. Statistical analysis was car-
ried out using SOLO (BMDP Statistical Software, Los
Angeles, CA, USA).
Results
Patient characteristics
A total of 54 patients were analyzed: at initial diagnosis,
most patients (83.3%) had serous ovarian carcinoma, and
presented with FIGO stage IIIC disease (n = 45, 83.3%)
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was 69 years (range = 40-89). Median PFI was 7.5 months
(range = 1-72); 20 patients (37.0%) were considered pri-
marily platinum refractory/resistant, while 34 patients
(63.0%) were defined as platinum sensitive (Table 1).
Median number of previous regimens was 4 (range =
1-9); in particular, 79.6% of patients had received ≥2 pre-
vious lines, and 37.0% of patients had received ≥5 prior
treatments before starting MOC. The vast majority of
patients (N = 40, 74.1%) had already been treated with
anthracyclines.
At time of MOC administration most patients pre-
sented with abdominal carcinomatosis only or associated
with other site of disease (N = 43, 79.6%), while only 11
patients presented with isolated parenchymal or lymph
node disease.Table 1 Clinico-pathological features of patients at time
of MOC administration
All cases (N = 54)
Age at diagnosis of recurrence, yrs
Median (range) 69 (40–89)
ECOG PS
0 20 (37.0)
1 18 (33.3)
2 16 (29.6)
Platinum sensitivity
Refractory/resistant 20 (37.0)
Sensitive 34 (63.0)
No. prior regimens
1-2 11 (20.4)
3-4 23 (42.6)
5-6 16 (29.6)
≥7 4 ( 7.4)
Previous anthracyclines
No 14 (25.9)
Yes 40 (74.1)
Pattern of recurrence
Carcinomatosis only 9 (16.7)
Carcinomatosis and parenchymal metastasis 8 (14.8)
Carcinomatosis and lymph node disease 14 (25.9)
Carcinomatosis, parenchymal metastases and
lymph node disease
12 (22.2)
Isolated parenchymal metastases or lymph
node disease
11 (20.4)
Ca125 levels (IU/ml) at baseline
Median (range) 508 (10–9,500)
≤35 I.U./ml 3 ( 5.6)
>35 I.U./ml 51 (94.4)Response to treatment
At time of analysis, all patients were assessable for re-
sponse (Table 2): in the overall series, 3 complete responses
(5.5%, 95% CI:-0.58, 11.6), and 8 partial responses (14.8%,
95% CI: 5.3, 24.3) have been registered, with an ORR of
20.4% (95% CI: 9.6, 31.0). Median response duration was
13 months (range = 3-35), and 8 out of 11 patients (72.7%)
had a response duration ≥6 months (data not shown).
Eleven patients (20.4%, 95% CI: 9.6, 31.0) experienced
stable disease (median duration: 6 months, range = 3-15),
and 8 of them had a response duration ≥6 months. Clinical
benefit (complete and partial response plus stable disease)
was achieved in 22 cases (40.7%, 95% CI: 27.6, 53.8), and
16 of them (72.7%) experienced a duration of clinical bene-
fit ≥6 months. A total of 32 patients (59.2.%, 95% CI: 46.1,
72.3) progressed during treatment.
In platinum refractory/resistant disease, we registered
1 complete and 2 partial responses (ORR = 15.0%; 95%
CI:-0.6, 30.6); stabilization of disease was observed in 6
out of 20 patients (30.0%, 95% CI: 9.9,50.1). In platinum
sensitive patients, ORR was 23.5% (95% CI: 9.2,37.8);
stabilization of disease was observed in 5 out of 34 pa-
tients (14.7%, 95% CI: 2.8, 26.7).
As shown in Table 3, response according to GCIG cri-
teria was significantly associated with RECIST defined
response to treatment: in particular, return of Ca125 to
normal levels, or ≥50% reduction compared to baseline
predicted ORR in 56.2% of cases, whereas lack of re-
sponse according to GCIG criteria predicted lack of
RECIST assessed response in all cases.
Patients with serous versus other tumor histotypes
showed a lower rate of response to MOC compared to
other tumor histotypes, although the statistical signifi-
cance was not reached.
Pattern of disease progression did not influence clin-
ical response to treatment. Finally, neither was there any
difference in response rate according to initial platinum
sensitivity, nor with number of previous chemotherapy
lines (Table 3).
Survival analysis
As of August 2013, follow up data were available for all
patients: median follow up duration was 10 months
(range: 4–43). During the follow up period, progression
and death of disease were observed in 52 (96.3%), and
37 (68.5%) cases, respectively.
In the whole series median PFS was 4 months, and the
12-month PFS rate was 19.6% (Figure 1A); median OS
was 13 months, and the 12-month OS rate was 51.5%
(Figure 1B). Patients achieving complete or partial response
to MOC showed a more favorable PFS (median =
17 months) compared to patients with stabilization (me-
dian = 6 months; p value = 0.009) or progression of disease
(median = 3 months; p value = 0.0001) (Figure 2A). Median
Table 2 Clinical response in the overall series and according to platinum sensitivity
N. Complete
N. (%) CI95%
Partial N. (%)
CI95%
ORR N. (%)
CI95%
Stable disease
N. (%) CI95%
Clinical benefit
N. (%) CI95%
PD N. (%)
CI95%
p valuea
All cases 54 3 ( 5.5) 8 (14.8) 11 (20.4) 11 (20.4) 22 (40.7) 32 (59.2)
−0.58,11.6 5.3, 24.3 9.6,31.0 9.6,31.0 27.6, 53.8 46.1,72.3
Refractory 20 1 ( 5.0) 2 (10.0) 3 (15.0) 6 (30.0) 9 (45.0) 11 (55.0)
Resistant −4.5, 14.6 −3.1,23.1 −0.6,30.6 9.9, 50.1 23.2, 66.8 33.2, 76.8
Sensitive 34 2 ( 5.9) 6 (17.6) 8 (23.5) 5 (14.7) 13 (38.2) 21 (61.7)
−2.0, 13.8 4.8,30.4 9,2,37.8 2.8, 26.7 21.9, 54.5 45.3, 78.0 0.5b
aCalculated by Fisher’s exact test for proportion.
bcomplete/partial versus stable disease/progression, in platinum sensitive versus platinum refractory/resistant disease.
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11 months in cases achieving stabilization (p value =
0.0011), or progression of disease (median = 8 months;
p value = 0.0001) (Figure 2B). There was no difference in
PFS curve according to initial platinum sensitivity (data
not shown).
Toxicity
A total of 370 courses were evaluable for toxicity, with a
median number of 4 cycles (range = 2-35) having been ad-
ministered per patient. Cumulative dose of MOC ranged
between 2,900 mg to 52,000 mg (median = 6,000 mg).
Hematological toxicity was documented in only 1 patient
who experienced grade 3 anemia. Non-hematological tox-
icity was registered in 4 patients: in particular, 1 patient
experienced grade 2 nausea/vomiting and grade 3 asthe-
nia, 1 patient showed grade 1 cutaneous toxicity, 1 patientTable 3 Variables associated with RECIST defined response to
Variable All cases N. C
GCIG response
Complete/Partial 16
SD/Progression 35
Histotype
Serous 45
Other 9
Pattern of recurrence
Carcinomatosis 43
Isolated lymph node or parenchymal disease 11
Platinum sensitivity
Refractory/resistant 20
Sensitive 34
No. previous chemotherapy lines
≤4 34
>4 20
aCalculated by Fisher’s exact test for proportion, bCalculated on 51 cases with basel
Percentages may not total 100% due to rounding.referred grade 1 pruritus, and 1 patient had to discontinue
treatment due to grade 3 gastritis.
Discussion
This retrospective, multicenter study was aimed at inves-
tigating the efficacy and toxicity of MOC in very heavily
treated ROC patients.
The very early study by Beck et al. [13], who utilized
MOC in 78 advanced ovarian cancer patients no longer
amenable to surgery or radiotherapy reported a response
rate of 48%; however, this figure referred to patients
treated during the time frame preceding the advent of
platinum agents in the scenario of medical treatment of
ovarian cancer. This consideration, together with the use
of response evaluation criteria completely different from
the current standard, intuitively precluded any reliable
comparison with our results. A more recent feasibilityCTX
Clinical response p valuea
omplete and Partial
response N. (%)
Stable and Progressive
disease N. (%)
9 (56.2) 7 (43.7)
0 35 (100) 0.0001b
7 (15.5) 38 (84.4)
4 (44.4) 5 (55.5) 0.07
9 (20.9) 34 (79.1)
2 (18.2) 9 (81.8) 0.69
3 (15.0) 17 (85.0)
8 (23.5) 26 (76.5) 0.51
7 (20.6) 27 (79.4)
4 (20.0) 16 (80.0) 0.38
ine Ca125 levels > 35 I.U./ml.
Figure 1 PFS (A) and OS (B) curves in the overall series.
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to MOC of 7.1%, while a retrospective review of a simi-
lar patient setting reported a 44% response rate [16];
nonetheless, the reliability of these data are heavily im-
paired by the very small sample series [15,16].
In this context, our study on 54 patients first allows to
more reliably assess i) the extent of clinical efficacy of
MOC, ii) the association between clinico-pathological
features and response, and iii) the impact of sensitivity
to MOC in terms of clinical outcome.
Indeed, MOC provided in our series an ORR of 20.4%, a
figure which appears in the range reported for other drugs
used in a similar setting [22,23]; the achievement of an
ORR of 15.0% in platinum resistant subgroup should also
be not underestimated considering the corresponding fig-
ures obtained with intravenously administered cytotoxic
drugs [3,22-25]. Moreover, 20.4% of patients experienced
stabilization of disease, thus leading to a rate of clinical
benefit of 40.8%, which seems clinically relevant consider-
ing that almost 80% of patients had already received ≥3
treatments before MOC administration.
In addition, the documentation of ≥6 month duration
of clinical benefit in about 30% of cases confirms earlier,
anedoctal experiences about MOC-induced long lasting
control of disease [14]; in this context, recent preclinical
and clinical evidences have demonstrated that metronomicFigure 2 PFS (A) and OS (B) according to response to MOC.cyclophosphamide used alone or in combination with
other agents is able to selectively reduce circulating im-
munosuppressive T-regulatory cells and myeloid de-
rived suppressor cells, while inducing antitumor T cell
response [25,26]; moreover, MOC has been also shown
to inhibit cancer stem cells in vitro and in vivo [27,28],
thus suggesting that MOC could act as a multi-targeted
approach [11,12].
As far as clinical outcome is concerned, median PFS
and OS were comparable to those achieved with other
cytotoxic agents in retrospective as well as phase II stud-
ies in heavily treated ROC [22-24]; moreover, patients
responding to MOC experienced a very favorable PFS
(median = 17 months), and OS (median = 30 months)
compared to non-responders. It remains to be clarified
why survival curves as well as tumor responsiveness did
not show any difference according to platinum sensitiv-
ity: it is conceivable that, given the not negligible num-
ber of chemotherapy lines preceding the administration
of MOC, the potential favorable implications of “plat-
inum-sensitivity” of disease as defined on the basis of
initial platinum-free interval could be less evident; alter-
natively, it cannot be excluded that the relatively low
number of platinum resistant/refractory patients could
have precluded the detection of a statistically significant
difference in clinical outcome between groups.
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fects of metronomic chemotherapy administration on
tumor microenvironment could sustain the independ-
ence of MOC activity from tumor cell sensitivity to the
drug [11,12].
As far as the toxicity is concerned, continuously ad-
ministered MOC at the dose of 50 mg daily appeared to
be well tolerated despite the number of previously ad-
ministered chemotherapy lines: indeed, grade 3 toxicity
was documented in 3 patients, and only 1 of them re-
quired treatment discontinuation. This profile of toxicity
thus appears more favorable compared to previously re-
ported experiences with MOC which, nonetheless, uti-
lized slightly higher doses of the drug, i.e. 50–150 mg
daily [13], or 50 mg twice a day for 3 weeks with a 1-
week break [15], or 50–150 mg d1-14, every 4 weeks
[16]. This observation, together with the recognized
anti-angiogenic activity of MOC have provided the ra-
tionale for its combination with bevacizumab in retro-
spective as well as prospective studies which showed
values of median PFS (range = 3.0-7.2 months) [29-31]
comparable to our and previous results [16]. However,
with the limits inherent to the direct comparison of dif-
ferent samples and studies, the combination MOC plus
bevacizumab appeared endowed with a higher percent-
age of treatment related adverse events [29-32], thus
highlighting the potential role of MOC as a valid alter-
native in terms of risk/benefit ratio.
In this context, the combination of MOC with other anti-
angiogenic drugs, such as nindetanib (NCT01610869) or
pazopanib (NCT01238770) (www.clinicaltrials.gov) seems
quite appealing. Finally, future therapeutic development for
MOC could be represented by combination with immuno-
therapeutic approaches [11,12,33].Conclusion
Metronomic oral administration of cyclophosphamide
single agent seems to provide a valid alternative in terms
of risk/benefit ratio in the scenario of palliative treat-
ments of heavily treated ROC patients, especially if af-
fected by several comorbidities.Competing interests
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